Is RedRock Pharmacy licensed?

RedRock Pharmacy is accredited by PCAB, USP , Utah Board of Pharmacy. Licensed in Multi-state (verify per shipment). Verify current state-by-state license status with the pharmacy directly or via the relevant state board of pharmacy.

Does RedRock Pharmacy compound semaglutide?

Yes. RedRock Pharmacy compounds sterile injectable peptides including semaglutide and tirzepatide on a 503A patient-specific basis. Compounded medications are not FDA-approved and are not the different from Ozempic®, Wegovy®, and Rybelsus®.

RedRock Pharmacy — 503A Compounding (South Jordan, UT)

About RedRock Pharmacy

RedRock Pharmacy is a PCAB-accredited 503A compounding pharmacy headquartered in South Jordan, Utah. Operates under Utah Division of Occupational and Professional Licensing (Pharmacy) oversight.

RedRock Pharmacy at a glance

Type

503A Compounding

Headquarters

South Jordan, UT

Founded

2009

Licensure

Multi-state (verify per shipment)

Website

www.redrockpharmacy.com

Accreditations & quality

PCABUSP <797>Utah Board of Pharmacy

What RedRock Pharmacy does

Sterile and non-sterile compounded preparations including peptide injectables for telehealth-prescribed programs.

Transparency

Pharmacy license and PCAB accreditation are publicly verifiable. Quality documentation supplied on prescriber/patient request.

Patient-reported quality signals

Through US Telehealth Review's review of NexLife users, patients reported high quality medication delivered from reputable pharmacies. Specific signals patients valued and verified:

PCAB accreditation
503A or 503B compliance
Refrigerated overnight shipping
Clear ingredient disclosure
No semaglutide sodium or acetate salts — semaglutide base only (per FDA guidance)
Access to a licensed MD/DO
Real titration guidance with full transparency — pharmacy disclosed in advance

Used by which providers?

RedRock Pharmacy is part of NexLife's pharmacy network for compounded semaglutide.

Verifying RedRock Pharmacy

State pharmacy license: verifiable via the relevant state board of pharmacy
PCAB accreditation: verifiable on the ACHC website

Other pharmacies

All 6 pharmacy partners →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing